Article: Why is it still drug discovery?
Matthew Segall (while still in the ADMET Division, BioFocus DPI), explored the balance between luck and judgement in drug discovery. As Matt put it “The vision of an in silico design process for drug molecules is certainly attractive, so
why has this goal yet to be realised, despite an enormous effort over the past 10 years?”
You can read a copy of this article as a PDF file.